962MO A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma

Activity: Talk or presentation › Talk or presentation at a conference

Period17 Sept 2021
Event titleESMO Congress 2021
Event typeConference
LocationParis, FranceShow on map
Degree of RecognitionInternational